News

For Immediate Release

Chicago, IL – July 11, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S NVO, AbbVie Inc. ABBV, AstraZeneca PLC AZN, Air T, Inc. AIRT and United-Guardian, Inc. UG.

Here are highlights from Wednesday’s Analyst Blog:

Top Stocks Reports for Novo Nordisk, AbbVie and AstraZeneca

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, AbbVie Inc. and AstraZeneca PLC, as well as two micro-cap stocks, Air T, Inc. and United-Guardian, Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Novo Nordisk shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+84.5% vs. +34.3%). The Zacks analyst believes that the company’s diabetes and obesity drugs segments have been driving business growth, and the company is also gearing up to buy Cardior to help diversify.

Yet, intense rivalry in the obesity sector threatens Novo Nordisk’s market share. Patent expiry and pricing pressure across the diabetes market also remain a major concern.

(You can read the full research report on Novo Nordisk here >>>)

AbbVie’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+23.9% vs. +34.3%). The Zacks analyst believes that the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on Imbruvica and decreased demand for fillers in international markets.

Yet, high costs and expenses related to projects and restructuring activities have remained as causes of concern.

(You can read the full research report on AbbVie here >>>)

Shares of AstraZeneca have underperformed the Zacks Large Cap Pharmaceuticals industry over the past two years (+14.8% vs. +38.9%). Per the Zacks analyst, the company’s diabetes franchise faces stiff competition while the respiratory unit is being hurt by pricing pressure.

Yet, a massive global presence, diverse product portfolio, external acquisitions and strategic collaborations to boost its pipeline are going to aid. Also, key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, Ultomiris and Farxiga should keep driving revenues.

(You can read the full research report on AstraZeneca here >>>)

Air T’s shares have outperformed the Zacks Transportation – Air Freight and Cargo industry over the past six months (+58.4% vs. -6.3%). The Zacks analyst believes that wise acquisitions, higher administrative fees and diversification across four segments have helped drive Air T’s growth in recent months. The WASI acquisition enhances service offerings and geographic reach, contributing to revenue growth. Equity investments and effective cost management bolster financial stability.

However, declining profit margins, high debt levels, negative cash flows, and sector-specific risks and operational losses remain major headwinds.

(You can read the full research report on Air T here >>>)

United-Guardian’s shares have outperformed the Zacks Medical – Products industry over the past year (+15.1% vs. -3.1%). The Zacks analyst believes that discontinuation of low-growth industrial products, focus on higher-margin segments, market strength in cosmetic ingredients and medical lubricants and being supported by a global customer base have helped grow UG’s business.

However, a significant reserve of slow-moving and obsolete inventory, concentration of key customers and supply chain vulnerabilities remain causes for concern.

(You can read the full research report on United-Guardian here >>>)

Why Haven’t You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How To Profit From Trillions On Spending For Infrastructure >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

United-Guardian, Inc. (UG): Free Stock Analysis Report

Air T, Inc. (AIRT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.